Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine ...

Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...

Bavarian Nordic's own pipeline is led by its universal COVID-19 booster candidate, which is due to start phase 3 later this year, and respiratory syncytial virus (RSV) candidate that should ...

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...

This recent safety and effectiveness data regarding mpox vaccination with Jynneos is important and timely given the ongoing ...

Jynneos was the first smallpox vaccine developed under Project BioShield, a program created by Congress in 2004 to accelerate ...

The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...